Exact Sciences stock exits Nasdaq after Abbott deal

Published on 10/14/2026 at 07:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott paid USD 105.00 per share on March 23, 2026. For Exact Sciences stock, fiscal 2025 revenue reached USD 3.25 billion, up 18.00 percent.

Abbott completes cancer diagnostics deal

Abbott completed the Exact Sciences acquisition for USD 105.00 per share on March 23, 2026.
Fiscal 2025 revenue reached USD 3.25 billion, up 18.00 percent.
The final Nasdaq quote was USD 104.91 on March 23, 2026.
The former Exact Sciences business contributed USD 1.0 billion in first-half 2026 sales inside Abbott.

Flatlay mit Aktienzertifikat ISIN US30063P1057, Laborröhrchen, DNA-Modell und Stethoskop — Exact Sciences Corp. Aktie US30063P1057 im Flatlay mit Aktienzertifikat und diagnostischen Laborutensilien, Illustration mit AI erstellt.

Exact Sciences stock exited Nasdaq after Abbott completed its acquisition for USD 105.00 per share on March 23, 2026. Ticker Scout reports that Exact Sciences became a direct, wholly owned Abbott subsidiary on that date, ending its independent public listing.

Abbott takes over cancer diagnostics

The transaction converted each Exact Sciences share into USD 105.00 in cash and established Abbott's Cancer Diagnostics business. The deal places Cologuard, Oncotype DX and Cancerguard inside Abbott's broader diagnostics portfolio, while Exact Sciences' historical results become part of Abbott's comparable-sales base.

The ownership change also fixes the final public-market valuation reference. A report from AInvest states that the Nasdaq ticker EXAS came off the board after the closing.

Revenue shows the operating base

Exact Sciences generated USD 3.25 billion in fiscal 2025 revenue, an 18.00 percent increase from the prior year, according to AInvest. The finance statement for fiscal 2025 reports revenue of USD 3.247 billion, net loss of USD 207.9 million and operating cash flow of USD 491.4 million.

That combination matters for Abbott's integration case: the acquired business brought scale in screening and precision oncology, but its historical fiscal 2025 loss shows why revenue growth alone does not describe the earnings profile. Abbott's later reporting placed Exact Sciences inside its Cancer Diagnostics business rather than presenting it as a standalone listed company.

The final Nasdaq quote

The last quoted Exact Sciences price was USD 104.91 on Nasdaq on March 23, 2026, while the final market capitalization was USD 20.0 billion on the same date. The USD 104.91 quote sat USD 0.09 below Abbott's USD 105.00 cash consideration.